Advertisement

Indian Journal of Gastroenterology

, Volume 37, Issue 3, pp 209–214 | Cite as

Raised plasma levels of H2S and nitrate predict intrapulmonary vascular dilations: A preliminary report in patients with cryptogenic cirrhosis

  • Chinmay Bera
  • Kavitha Thangaraj
  • Purendra Kumar Pati
  • Jeyamani Ramachandran
  • K A Balasubramanian
  • Anup Ramachandran
  • Uday Zachariah
  • K G Sajith
  • Ashish Goel
  • C E EapenEmail author
Original Article
  • 80 Downloads

Abstract

Background and Aims

The role of vasoactive chemicals in the pathogenesis of hepatopulmonary syndrome (HPS), a disorder characterized by intrapulmonary vascular dilation (IPVD), is only vaguely elucidated. We aimed to study the association between plasma H2S, nitrate levels, and presence and severity of IPVD and HPS.

Methods

Consecutive adult patients with cryptogenic cirrhosis were evaluated for IPVD (by contrast echocardiography) and for hypoxemia (by arterial blood gas analysis). Plasma H2S and nitrate levels were measured in these patients.

Results

Fifty-eight patients with cryptogenic cirrhosis (male, 45; median age, range, 45, 16–74 years; Child’s class; A, 30; B, 18; C, 10) were enrolled in this study. Thirty-four of the 58 (59%) patients had IPVD and 13 (22%) had HPS (mild, 4; moderate, 5; severe, 2; very severe, 2). Plasma H2S levels were significantly higher in patients with IPVD (19.6, 5.7–83 μmol/L) as compared to patients who had no IPVD (12.3, 0–47 μmol/L; p-value 0.03) with an area under receiver operating characteristic curve of 0.68 (95% CI 0.53–0.84). Plasma H2S levels were higher in patients with IPVD irrespective of liver disease severity. There was a trend for higher plasma nitrate levels in patients with IPVD (47, 15.8–126.4 nmol/mL) as compared to patients who had no IPVD (32.3, 6.9–51.4 nmol/mL; p-value 0.1). Raised plasma H2S and nitrate levels had an additive effect on the presence of IPVD. Neither plasma H2S nor plasma nitrate levels correlated with the degree of hypoxemia.

Conclusion

Raised plasma H2S and nitrate levels predict the presence of IPVD in patients with cryptogenic cirrhosis.

Keywords

Hepatopulmonary syndrome Nitric oxide Sulfate 

Notes

Acknowledgments

The authors wish to acknowledge the role of Professor Elwyn Elias, Liver Unit, University Hospital Birmingham, Birmingham, UK, in study concept and critical revision of the manuscript.

Financial support

Authors acknowledge and thank the financial support rendered by institutional Fluid Research Fund of Christian Medical College, Vellore, India.

Compliance with ethical standards

Conflict of interest

CB, KT, PKP, JR, KAB, AR, UZ, KGS, AG, and CEE declare that they have no conflict of interest.

Ethics statement

The study was performed in a manner to conform with the Helsinki Declaration of 1975, as revised in 2000 and 2008 concerning human and animal rights, and the authors followed the policy concerning informed consent as shown on Springer.com. The study protocol was approved by the institutional review board and ethics committee.

References

  1. 1.
    Lv Y, Fan D. Hepatopulmonary syndrome. Dig Dis Sci. 2015;60:1914–23.CrossRefPubMedGoogle Scholar
  2. 2.
    Raevens S, Geerts A, Steenkiste CV, Verhelst X, Vlierberghe HV, Colle I. Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment. Liver Int. 2015;35:1646–60.CrossRefPubMedGoogle Scholar
  3. 3.
    Zhang M, Luo B, Chen SJ, Abrams GA, Fallon MB. Endothelin-1 stimulation of endothelial nitric oxide synthase in the pathogenesis of hepatopulmonary syndrome. Am J Phys. 1999;277:G944–52.Google Scholar
  4. 4.
    Zhang XJ, Katsuta Y, Aikmoto T, Ohsuga M, Aramaki T, Takano T. Intrapulmonary vascular dilatation and nitric oxide in hypoxemic rats with chronic bile duct ligation. J Hepatol. 2003;39:724–30.CrossRefPubMedGoogle Scholar
  5. 5.
    Arquedas MR, Drake BB, Kapoor A, Fallon MB. Carboxyhemoglobin levels in cirrhotic patients with and without hepatopulmonary syndrome. Gastroenterology. 2005;128:328–33.CrossRefGoogle Scholar
  6. 6.
    Rabiller A, Nunes H, Lebrec D, et al. Prevention of gram-negative translocation reduces the severity of hepatopulmonary syndrome. Am J Respir Crit Care Med. 2002;166:514–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Zhang J, Luo B, Tang L, et al. Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome. Gastroenterology. 2009;136:1070–80.CrossRefPubMedGoogle Scholar
  8. 8.
    Cheng Y, Ndisang JF, Tang G, Cao K, Wang R. Hydrogen sulphide-induced relaxation of resistance mesenteric beds of rats. Am J Physiol Heart Circ Physiol. 2004;287:H2316–23.CrossRefPubMedGoogle Scholar
  9. 9.
    Szabo C, Papapetropoulos P. Hydrogen sulphide and angiogenesis: mechanisms and applications. Br J Pharmacol. 2011;164:853–65.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Aller R, Moya JL, Moreira V, et al. Diagnosis of hepatopulmonary syndrome with contrast transesophageal echocardiography. Advantages over contrast transtoracic echocardiography. Dig Dis Sci. 1999;44:1243–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Ahmad FD, Sattar MA, Rathore HA, et al. Exogenous hydrogen sulfide (h2s) improves the endothelial and renal excretory functions in streptozotocin induced wky diabetic rats. IJPSR. 2012;3:101–10.Google Scholar
  12. 12.
    Sastry KVH, Moudgal RP, Mohan J, Tyagi JS, Rao GS. Spectrophotometric determination of serum nitrite and nitrate by copper-cadmium alloy. Anal Biochem. 2002;306:79–82.CrossRefPubMedGoogle Scholar
  13. 13.
    Beltowski J. Hydrogen sulphide in pharmacology and medicine—an update. Pharmacol Rep. 2015;67:647–58.CrossRefPubMedGoogle Scholar
  14. 14.
    Yang G, Wu L, Jiang B, et al. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science. 2008;322:587–90.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Fiorucci S, Antonelli E, Mencarelli A, et al. The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. Hepatology. 2005;42:539–48.CrossRefPubMedGoogle Scholar
  16. 16.
    Rey FE, Gonzalez MD, Cheng J, Wu M, Ahern PP, Gordon JI. Metabolic niche of a prominent sulfate-reducing human gut bacterium. Proc Natl Acad Sci U S A. 2013;110:13582–7.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Ritz NL, Burnett BJ, Setty P, et al. Sulfate-reducing bacteria impairs working memory in mice. Physiol Behav. 2016;157:281–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Beaumont M, Andriamihaja M, Lan A, et al. Detrimental effects for colonocytes of an increased exposure to luminal hydrogen sulfide: the adaptive response. Free Radic Biol Med. 2016;93:155–64.CrossRefPubMedGoogle Scholar
  19. 19.
    Picton R, Eggo MC, Merrill GA, Langman MJ, Singh S. Mucosal protection against sulphide: importance of the enzyme rhodanese. Gut. 2002;50:201–5.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Norris EJ, Culberson CR, Narasimhan S, Clemens MG. The liver as a central regulator of hydrogen sulfide. Shock. 2011;36:242–50.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Mani S, Cao W, Wu L, Wang R. Hydrogen sulfide and the liver. Nitric Oxide. 2014;41:62–71.CrossRefPubMedGoogle Scholar
  22. 22.
    Song K, Li Q, Yin XY, Lu Y, Liu CF, Hu LF. Hydrogen sulfide: a therapeutic candidate for fibrotic disease? Oxidative Med Cell Longev. 2015;2015:458720.Google Scholar
  23. 23.
    Wu D, Wang J, Li H, Xue M, Ji A, Li Y. Role of hydrogen sulfide in ischemia-reperfusion injury. Oxidative Med Cell Longev. 2015;2015:186908.Google Scholar
  24. 24.
    Ebrahimkhani MR, Mani AR, Moore K. Hydrogen sulphide and the hyperdynamic circulation in cirrhosis: a hypothesis. Gut. 2005;54:1668–71.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Iwakiri Y, Kim YM. Nitric oxide in liver diseases. Trends Pharmacol Sci. 2015;6:524–36.CrossRefGoogle Scholar
  26. 26.
    Ames PR, Guardascione M, Batuca JR, Arcaro A, Gentile F, Amitrano L. Nitric oxide metabolites, nitrative stress, and paraoxonase activity in hepatopulmonary syndrome. Scand J Gastroenterol. 2016;51:73–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Feng G, Rong H. The role of hemodynamic and vasoactive substances on hepatopulmonary syndrome. Eur Rev Med Pharmacol Sci. 2014;18:380–6.PubMedGoogle Scholar

Copyright information

© Indian Society of Gastroenterology 2018

Authors and Affiliations

  • Chinmay Bera
    • 1
  • Kavitha Thangaraj
    • 2
  • Purendra Kumar Pati
    • 3
  • Jeyamani Ramachandran
    • 1
  • K A Balasubramanian
    • 2
  • Anup Ramachandran
    • 2
  • Uday Zachariah
    • 1
  • K G Sajith
    • 1
  • Ashish Goel
    • 1
  • C E Eapen
    • 1
    Email author
  1. 1.Department of HepatologyChristian Medical CollegeVelloreIndia
  2. 2.Wellcome Trust Research LaboratoriesChristian Medical CollegeVelloreIndia
  3. 3.Department of CardiologyChristian Medical CollegeVelloreIndia

Personalised recommendations